8-K filed Aug 6, 2026 at 07:12 ET
Ironwood Pharmaceuticals reported Q2 2026 GAAP EPS of $0.31, beating the $0.28 consensus by 10.7%, on revenue of $113.0M (slightly below the $114.7M estimate). The company raised full-year 2026 guidance: LINZESS U.S. net sales to $1.15-$1.20B (from $1.125-$1.175B), total revenue to $460-$485M (from $450-$475M), and adjusted EBITDA to >$310M (from >$300M). The beat was driven by strong LINZESS performance (14% YoY net sales growth, 78% commercial margin) and the company repaid its $200M convertible notes with cash on hand, strengthening the balance sheet. The STARS-2 Phase 3 trial for apraglutide is now actively recruiting patients.